| 1 | Cancer Incidence and Trends in Persistent Poverty Areas of California by Race/Ethnicity and Sex | 2.6 | 0 | Citations (PDF) |
| 2 | Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018 | 2.0 | 3 | Citations (PDF) |
| 3 | Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study | 5.5 | 5 | Citations (PDF) |
| 4 | Association of IVCF use with mortality and intracranial hemorrhage in patients with selected cancers and brain metastasis | 0.0 | 0 | Citations (PDF) |
| 5 | Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry | 5.0 | 1 | Citations (PDF) |
| 6 | The clinical spectrum of HbSC sickle cell disease‐not a benign condition | 2.7 | 21 | Citations (PDF) |
| 7 | Rates of strokes in Californians with sickle cell disease in the post-STOP eraBlood, 2024, 144, 2517-2527 | 4.8 | 14 | Citations (PDF) |
| 8 | A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisisBlood, 2023, 141, 168-179 | 4.8 | 38 | Citations (PDF) |
| 9 | Pregnancy outcomes in women with sickle cell disease in California | 6.5 | 32 | Citations (PDF) |
| 10 | Predicting venous thromboembolism (VTE) risk in cancer patients using machine learning | 2.5 | 5 | Citations (PDF) |
| 11 | The incidence of cancer-associated thrombosis is increasing over time | 5.0 | 142 | Citations (PDF) |
| 12 | Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI | 5.0 | 15 | Citations (PDF) |
| 13 | Stage at diagnosis and survival among adolescents and young adults with lymphomas following the Affordable Care Act implementation in California | 4.3 | 11 | Citations (PDF) |
| 14 | Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers | 4.1 | 18 | Citations (PDF) |
| 15 | Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors | 1.4 | 4 | Citations (PDF) |
| 16 | Racial disparities in cancer-associated thrombosis | 5.0 | 29 | Citations (PDF) |
| 17 | Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults | 3.2 | 1 | Citations (PDF) |
| 18 | Treatment at Specialized Cancer Centers Is Associated with Improved Survival in Adolescent and Young Adults with Soft Tissue Sarcoma | 1.7 | 14 | Citations (PDF) |
| 19 | COVID-19 and venous thromboembolism risk in patients with sickle cell disease | 5.0 | 8 | Citations (PDF) |
| 20 | Sickle Cell Disease | 16.5 | 411 | Citations (PDF) |
| 21 | Linking the Center for International Blood and Marrow Transplant Research Registry to the California Cancer Registry and California Hospital Patient Discharge Data | 2.0 | 5 | Citations (PDF) |
| 22 | Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients | 5.5 | 22 | Citations (PDF) |
| 23 | Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population‐based study | 1.3 | 7 | Citations (PDF) |
| 24 | Urban–Rural Variations in Quality of Care Among Patients With Cancer in California | 3.2 | 21 | Citations (PDF) |
| 25 | Safety of light emitting diode‐red light on human skin: Two randomized controlled trials | 2.0 | 36 | Citations (PDF) |
| 26 | Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia | 1.6 | 29 | Citations (PDF) |
| 27 | Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality | 1.4 | 13 | Citations (PDF) |
| 28 | Impact of insurance type and timing of Medicaid enrollment on survival among adolescents and young adults with cancer | 1.3 | 21 | Citations (PDF) |
| 29 | Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium | 6.5 | 46 | Citations (PDF) |
| 30 | Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia | 2.9 | 20 | Citations (PDF) |
| 31 | Chronic medical conditions and late effects following non‐Hodgkin lymphoma in HIV‐uninfected and HIV‐infected adolescents and young adults: a population‐based study | 2.7 | 18 | Citations (PDF) |
| 32 | High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma | 1.4 | 9 | Citations (PDF) |
| 33 | Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients | 2.7 | 11 | Citations (PDF) |
| 34 | Bleeding in patients with sickle cell disease: a population-based study | 5.0 | 35 | Citations (PDF) |
| 35 | Disparities in the Occurrence of Late Effects following Treatment among Adolescent and Young Adult Melanoma Survivors | 1.1 | 13 | Citations (PDF) |
| 36 | Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma | 4.6 | 24 | Citations (PDF) |
| 37 | A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia | 6.5 | 12 | Citations (PDF) |
| 38 | Detecting opioid metabolites in exhaled breath condensate (EBC) | 2.9 | 18 | Citations (PDF) |
| 39 | High incidence of venous thromboembolism recurrence in patients with sickle cell disease | 6.5 | 39 | Citations (PDF) |
| 40 | Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis | 2.9 | 69 | Citations (PDF) |
| 41 | The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update | 2.5 | 82 | Citations (PDF) |
| 42 | Impact of Health Insurance on Stage at Cancer Diagnosis Among Adolescents and Young Adults | 4.6 | 52 | Citations (PDF) |
| 43 | Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer | 34.5 | 683 | Citations (PDF) |
| 44 | Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California | 2.9 | 13 | Citations (PDF) |
| 45 | Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012–2013 in the United States | 1.3 | 50 | Citations (PDF) |
| 46 | Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer | 5.4 | 162 | Citations (PDF) |
| 47 | Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors | 1.7 | 45 | Citations (PDF) |
| 48 | Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute‐designated cancer centers in California | 4.0 | 54 | Citations (PDF) |
| 49 | Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California | 1.4 | 3 | Citations (PDF) |
| 50 | Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study | 2.1 | 50 | Citations (PDF) |
| 51 | Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence | 1.8 | 5 | Citations (PDF) |
| 52 | The sickle cell disease implementation consortium: Translating evidence‐based guidelines into practice for sickle cell disease | 6.5 | 69 | Citations (PDF) |
| 53 | How I diagnose and treat venous thromboembolism in sickle cell diseaseBlood, 2018, 132, 1761-1769 | 4.8 | 41 | Citations (PDF) |
| 54 | Complications and early mortality in patients with acute promyelocytic leukemia treated in California | 6.5 | 17 | Citations (PDF) |
| 55 | Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial | 2.3 | 125 | Citations (PDF) |
| 56 | Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia | 2.7 | 56 | Citations (PDF) |
| 57 | Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality | 2.7 | 125 | Citations (PDF) |
| 58 | Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study | 2.3 | 40 | Citations (PDF) |
| 59 | Increased risk of leukemia among sickle cell disease patients in CaliforniaBlood, 2017, 130, 1597-1599 | 4.8 | 136 | Citations (PDF) |
| 60 | Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flowBlood, 2017, 130, 2101-2110 | 4.8 | 94 | Citations (PDF) |
| 61 | Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial | 4.1 | 58 | Citations (PDF) |
| 62 | Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California | 5.0 | 87 | Citations (PDF) |
| 63 | Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance | 5.5 | 26 | Citations (PDF) |
| 64 | A multidimensional FPLC approach for the purification of recombinant non‐coding RNAs | 0.6 | 0 | Citations (PDF) |
| 65 | Sickle cell disease: an inherited thrombophilia | 2.7 | 55 | Citations (PDF) |
| 66 | Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism | 18.0 | 78 | Citations (PDF) |
| 67 | Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy | 1.6 | 7 | Citations (PDF) |
| 68 | Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in CaliforniaBlood, 2016, 128, 2489-2489 | 4.8 | 24 | Citations (PDF) |
| 69 | Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM)Blood, 2016, 128, 846-846 | 4.8 | 3 | Citations (PDF) |
| 70 | Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based StudyBlood, 2016, 128, 3982-3982 | 4.8 | 4 | Citations (PDF) |
| 71 | Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over TimeBlood, 2016, 128, 2375-2375 | 4.8 | 0 | Citations (PDF) |
| 72 | Sociodemographic Factors Predict Medical Conditions Among Five-Year Survivors of Adolescent and Young Adult Hodgkin LymphomaBlood, 2016, 128, 693-693 | 4.8 | 0 | Citations (PDF) |
| 73 | Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in CaliforniaBlood, 2016, 128, 391-391 | 4.8 | 0 | Citations (PDF) |
| 74 | Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid useBlood, 2015, 125, 2656-2664 | 4.8 | 198 | Citations (PDF) |
| 75 | Vena Cava Filter Use in Cancer Patients with Acute Venous Thromboembolism in California | 2.3 | 14 | Citations (PDF) |
| 76 | Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized TrialBlood, 2015, 126, 427-427 | 4.8 | 12 | Citations (PDF) |
| 77 | Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic ImpactBlood, 2015, 126, 1305-1305 | 4.8 | 0 | Citations (PDF) |
| 78 | The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern TreatmentBlood, 2015, 126, 1991-1991 | 4.8 | 0 | Citations (PDF) |
| 79 | Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia | 2.3 | 66 | Citations (PDF) |
| 80 | Adverse Impact of Venous Thromboembolism on Patients with Cancer | 2.5 | 8 | Citations (PDF) |
| 81 | Multiplexed measurements of immunomodulator levels in peripheral blood of healthy subjects: Effects of analytical variables based on anticoagulants, age, and gender 2014, 86, 426-435 | | 23 | Citations (PDF) |
| 82 | Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential Therapeutics | 2.2 | 45 | Citations (PDF) |
| 83 | Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis | 2.6 | 75 | Citations (PDF) |
| 84 | Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive CrisisBlood, 2014, 124, 2704-2704 | 4.8 | 5 | Citations (PDF) |
| 85 | A Phase 3 Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia | 4.8 | 25 | Citations (PDF) |
| 86 | Homocysteine is associated with microvascular abnormalities in sickle cell disease (827.13) | 0.6 | 0 | Citations (PDF) |
| 87 | A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab EraBlood, 2014, 124, 2609-2609 | 4.8 | 0 | Citations (PDF) |
| 88 | A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease | 24.1 | 66 | Citations (PDF) |
| 89 | Biomolecular markers of cancer-associated thromboembolism | 5.0 | 34 | Citations (PDF) |
| 90 | The Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS) | 0.7 | 6 | Citations (PDF) |
| 91 | High Variation Between Hospitals in Vena Cava Filter Use for Venous Thromboembolism | 10.6 | 71 | Citations (PDF) |
| 92 | Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopeniaBlood, 2013, 121, 4782-4790 | 4.8 | 202 | Citations (PDF) |
| 93 | An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell AnemiaBlood, 2013, 122, 2206-2206 | 4.8 | 2 | Citations (PDF) |
| 94 | Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell DiseaseBlood, 2013, 122, 775-775 | 4.8 | 2 | Citations (PDF) |
| 95 | GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell DiseaseBlood, 2013, 122, 776-776 | 4.8 | 8 | Citations (PDF) |
| 96 | Predictors Of Vena Cava Filter Use For Venous Thromboembolism In Cancer PatientsBlood, 2013, 122, 935-935 | 4.8 | 0 | Citations (PDF) |
| 97 | Outcomes After Vena Cava Filter Placement In Cancer Patients Hospitalized For Acute Venous ThromboembolismBlood, 2013, 122, 936-936 | 4.8 | 0 | Citations (PDF) |
| 98 | Radioimmunotherapy | 6.2 | 4 | Citations (PDF) |
| 99 | Exchange Transfusion Therapy and Its Effects on Real-time Microcirculation in Pediatric Sickle Cell Anemia Patients | 0.7 | 15 | Citations (PDF) |
| 100 | Risk assessment models for cancer‐associated venous thromboembolism | 4.0 | 39 | Citations (PDF) |
| 101 | Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State | 4.8 | 1 | Citations (PDF) |
| 102 | Increased Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor (sLOX-1) and Increased Endothelial Cell Expression of LOX-1 in Sickle Cell Disease (SCD): A Novel Marker for SCD Vasculopathy?Blood, 2012, 120, 246-246 | 4.8 | 0 | Citations (PDF) |
| 103 | Monocyte Chemotactic Protein-1 Is Associated with Microvascular Abnormalities and Serum Ferritin Concentrations in Sickle Cell Disease PatientsBlood, 2012, 120, 3255-3255 | 4.8 | 0 | Citations (PDF) |
| 104 | Cancer Health Empowerment for Living without Pain (Ca-HELP): effects of a tailored education and coaching intervention on pain and impairmentPain, 2011, 152, 1572-1582 | 4.2 | 65 | Citations (PDF) |
| 105 | Splenectomy and the Incidence of Venous Thromboembolism and Sepsis In Patients with Immune Thrombocytopenia,Blood, 2011, 118, 3284-3284 | 4.8 | 1 | Citations (PDF) |
| 106 | A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell DiseaseBlood, 2011, 118, 847-847 | 4.8 | 5 | Citations (PDF) |
| 107 | Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070Blood, 2011, 118, 851-851 | 4.8 | 3 | Citations (PDF) |
| 108 | Incidence and Risk Factors for Intracranial Hemorrhage in Californians with Immune ThrombocytopeniaBlood, 2011, 118, 1161-1161 | 4.8 | 0 | Citations (PDF) |
| 109 | Increased Incidence of Hematological Malignancies Among Californians with Sickle Cell DiseaseBlood, 2011, 118, 1073-1073 | 4.8 | 0 | Citations (PDF) |
| 110 | Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell DiseaseBlood, 2011, 118, 2127-2127 | 4.8 | 0 | Citations (PDF) |
| 111 | Mightier than the sickle cellBlood, 2010, 116, 1633-1633 | 4.8 | 2 | Citations (PDF) |
| 112 | The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer | 4.0 | 54 | Citations (PDF) |
| 113 | Comparison of real‐time microvascular abnormalities in pediatric and adult sickle cell anemia patients | 6.5 | 34 | Citations (PDF) |
| 114 | Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism | 3.8 | 30 | Citations (PDF) |
| 115 | Emergency Department Sickle Cell Assessment of Needs and Strengths (ED‐SCANS), a Focus Group and Decision Support Tool Development Project | 1.7 | 17 | Citations (PDF) |
| 116 | GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell DiseaseBlood, 2010, 116, 1632-1632 | 4.8 | 6 | Citations (PDF) |
| 117 | Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 StudyBlood, 2010, 116, 262-262 | 4.8 | 4 | Citations (PDF) |
| 118 | Identification of Novel Peptide Ligands Targeting α4β1 Integrins on Patient Lymphoma CellsBlood, 2010, 116, 4854-4854 | 4.8 | 0 | Citations (PDF) |
| 119 | Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes In Sickle Cell Patients Not In CrisisBlood, 2010, 116, 2672-2672 | 4.8 | 0 | Citations (PDF) |
| 120 | Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors | 1.6 | 168 | Citations (PDF) |
| 121 | UC Davis CTSA: Coming of Age | 2.7 | 3 | Citations (PDF) |
| 122 | A comparison of multiplex suspension array large‐panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients | 1.6 | 61 | Citations (PDF) |
| 123 | Jumpstarting Academic Careers with a Novel Intern Research Rotation: the AIMS Rotation | 2.0 | 11 | Citations (PDF) |
| 124 | Epidemiology of cancer-related venous thromboembolism | 1.7 | 225 | Citations (PDF) |
| 125 | Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survivalBlood, 2009, 113, 3911-3917 | 4.8 | 171 | Citations (PDF) |
| 126 | The California Sickle Cell Database.Blood, 2009, 114, 1530-1530 | 4.8 | 0 | Citations (PDF) |
| 127 | Emergency Department Follow-up for Adults with Sickle Cell Disease.Blood, 2009, 114, 241-241 | 4.8 | 0 | Citations (PDF) |
| 128 | Overcoming barriers to cancer clinical trial accrual | 4.0 | 68 | Citations (PDF) |
| 129 | The incidence of venous thromboembolism among patients with primary lung cancer | 3.8 | 278 | Citations (PDF) |
| 130 | Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients | 24.1 | 39 | Citations (PDF) |
| 131 | Positron Emission Tomography and Improved Survival in Patients With Lung Cancer<subtitle>The Will Rogers Phenomenon Revisited</subtitle> | 8.1 | 93 | Citations (PDF) |
| 132 | Usefulness of Optical Density Values From Heparin–Platelet Factor 4 Antibody Testing and Probability Scoring Models to Diagnose Heparin-Induced Thrombocytopenia | 0.7 | 42 | Citations (PDF) |
| 133 | Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk? | 2.3 | 45 | Citations (PDF) |
| 134 | Polyurethane Shape-Memory Polymers Demonstrate Functional Biocompatibility In Vitro | 4.0 | 67 | Citations (PDF) |
| 135 | Venous thromboembolism in ovarian cancer | 3.0 | 152 | Citations (PDF) |
| 136 | A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.Blood, 2007, 110, 3216-3216 | 4.8 | 0 | Citations (PDF) |
| 137 | Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin | 3.0 | 21 | Citations (PDF) |
| 138 | Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival | 16.9 | 343 | Citations (PDF) |
| 139 | Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical Trials | 16.9 | 133 | Citations (PDF) |
| 140 | B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis | 1.3 | 2 | Citations (PDF) |
| 141 | Acute myocardial infarction in hemoglobin SC disease | 1.5 | 8 | Citations (PDF) |
| 142 | Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma | 0.7 | 88 | Citations (PDF) |
| 143 | Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature | 6.5 | 24 | Citations (PDF) |
| 144 | Inflammatory potential of neutrophils detected in sickle cell disease | 6.5 | 75 | Citations (PDF) |
| 145 | Effects of Poloxamer 188 Treatment on Sickle Cell Vaso-occlusive Crisis: Computer-Assisted Intravital Microscopy Study | 1.7 | 4 | Citations (PDF) |
| 146 | Effects of Poloxamer 188 Treatment on Sickle Cell Vaso-occlusive Crisis: Computer-Assisted Intravital Microscopy Study | 1.7 | 25 | Citations (PDF) |
| 147 | Effects of Poloxamer 188 Treatment on Sickle Cell Vaso-occlusive Crisis: Computer-Assisted Intravital Microscopy Study | 1.7 | 7 | Citations (PDF) |
| 148 | Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin | 4.0 | 140 | Citations (PDF) |
| 149 | Postprandial Lipemia is Associated With Platelet and Monocyte Activation and Increased Monocyte Cytokine Expression in Normolipemic Men | 1.7 | 79 | Citations (PDF) |
| 150 | Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy studyBlood, 2002, 99, 3999-4005 | 4.8 | 93 | Citations (PDF) |
| 151 | The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function | 2.3 | 172 | Citations (PDF) |
| 152 | Acetaminophen and diphenhydramine as premedication for platelet transfusions: A prospective randomized double-blind placebo-controlled trial | 6.5 | 92 | Citations (PDF) |
| 153 | Filgrastim Treatment of Acute Myelogenous Leukemia (M7) Relapse after Allogeneic Peripheral Stem Cell Transplantation Resulting in Both Graft-versus-Leukemia Effect with Cytogenetic Remission and Chronic Graft-versus-Host Disease Manifesting as Polyserositis and Subsequent Bronchiolitis Obliterans with Organizing Pneumonia | 1.5 | 7 | Citations (PDF) |
| 154 | Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant | 1.5 | 10 | Citations (PDF) |
| 155 | Early diagnosis and successful treatment of a patient with transfusion‐associated GVHD with autologous peripheral blood progenitor cell transplantation | 0.8 | 38 | Citations (PDF) |
| 156 | Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease* | 0.1 | 65 | Citations (PDF) |
| 157 | Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell diseaseBlood, 2001, 97, 3401-3404 | 4.8 | 35 | Citations (PDF) |
| 158 | Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study | 7.7 | 48 | Citations (PDF) |
| 159 | Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease | 16.5 | 184 | Citations (PDF) |
| 160 | Cocoa inhibits platelet activation and function | 4.7 | 328 | Citations (PDF) |
| 161 | Cocoa and Wine Polyphenols Modulate Platelet Activation and Function | 2.9 | 161 | Citations (PDF) |
| 162 | Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome | 2.0 | 95 | Citations (PDF) |
| 163 | Platelet activation in patients with sickle cell disease | 2.7 | 131 | Citations (PDF) |
| 164 | Platelet activation during dobutamine stress echocardiography | 2.9 | 22 | Citations (PDF) |
| 165 | High Concentrations of Thrombopoietin Activate Platelets In Vitro | 1.7 | 3 | Citations (PDF) |
| 166 | Vasopressin and platelets: a concise review | 2.4 | 21 | Citations (PDF) |
| 167 | Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia | 2.2 | 149 | Citations (PDF) |
| 168 | Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro | 6.5 | 37 | Citations (PDF) |
| 169 | Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma | 4.0 | 12 | Citations (PDF) |
| 170 | Physiologic concentrations of arginine vasopressin activate human platelets
in vitro | 2.7 | 54 | Citations (PDF) |
| 171 | Increased risk of cardiac death after therapy for Hodgkin's disease [letter; comment]Blood, 1994, 83, 2750-2750 | 4.8 | 0 | Citations (PDF) |
| 172 | Prolonged circulation of activated platelets following plasmapheresis | 2.4 | 34 | Citations (PDF) |
| 173 | Removal by white cell-reduction filters of activated platelets expressing CD62 | 0.8 | 31 | Citations (PDF) |
| 174 | Early manifestation of thrombotic thrombocytopenic purpura | 2.0 | 11 | Citations (PDF) |
| 175 | The Felty Syndrome and G-CSF-Associated Thrombocytopenia and Severe Anemia | 9.6 | 22 | Citations (PDF) |
| 176 | Detection of plasmapheresis-induced platelet activation using monoclonal antibodies | 0.8 | 33 | Citations (PDF) |
| 177 | Clonal remission in aplastic anemia after treatment with antithymocyte globulin | 6.5 | 4 | Citations (PDF) |
| 178 | ASH sickle cell disease CPKD guidelines report | 5.0 | 0 | Citations (PDF) |
| 179 | Low bone mineral density and pain impact in adults with sickle cell disease | 5.0 | 2 | Citations (PDF) |
| 180 | Sickle cell disease: managing thromboembolism | 2.7 | 0 | Citations (PDF) |
| 181 | High variation of inpatient admission rates between hospitals for cancer-associated pulmonary embolism in California | 4.8 | 0 | Citations (PDF) |
| 182 | Platelet-Erythrocyte Adhesion in Sickle Cell Disease | 1.7 | 2 | Citations (PDF) |
